Abstract
BackgroundDistinguishing between different types of thyroid cancers (TC) remains challenging in clinical laboratories. As different tumor types require different clinical interventions, it is necessary to establish new methods for accurate diagnosis of TC.MethodsProteomic analysis of the human serum was performed through data-independent acquisition mass spectrometry for 29 patients with TC (stages I–IV): 13 cases of papillary TC (PTC), 10 cases of medullary TC (MTC), and six cases follicular TC (FTC). In addition, 15 patients with benign thyroid nodules (TNs) and 10 healthy controls (HCs) were included in this study. Subsequently, 17 differentially expressed proteins were identified in 291 patients with TC, including 247 with PTC, 38 with MTC, and six with FTC, and 69 patients with benign TNs and 176 with HC, using enzyme-linked immunosorbent assays.ResultsIn total, 517 proteins were detected in the serum samples using an Orbitrap Q-Exactive-plus mass spectrometer. The amyloid beta A4 protein, apolipoprotein A-IV, gelsolin, contactin-1, gamma-glutamyl hydrolase, and complement factor H-related protein 1 (CFHR1) were selected for further analysis. The median serum CFHR1 levels were significantly higher in the MTC and FTC groups than in the PTC and control groups (P < 0.001). CFHR1 exhibited higher diagnostic performance in distinguishing patients with MTC from those with PTC (P < 0.001), with a sensitivity of 100.0%, specificity of 85.08%, area under the curve of 0.93, and detection cut-off of 0.92 ng/mL.ConclusionCFHR1 may serve as a novel biomarker to distinguish PTC from MTC with high sensitivity and specificity.
Highlights
Thyroid cancer (TC) is the eighth most common cancer in women, and it is known to be the most prevalent endocrine malignancy worldwide, with its incidence continuing to increase in recent years (Pellegriti et al, 2013)
Novel circulating protein biomarkers for thyroid cancer determined through data-independent acquisition mass spectrometry
thyroid cancers (TC) can be divided into two main groups of neoplasias based on their cell types: one includes carcinomas originating from the follicular epithelium, representing over 95% of all TCs, including papillary TC (PTC, 85%), follicular TC (FTC, 11%), Hurthle cell TC (3%), and anaplastic TC (ATC, 1%), while the other includes medullary TCs (MTCs) originating from the parafollicular thyroid cells, which make up less than 5% of all TCs
Summary
Thyroid cancer (TC) is the eighth most common cancer in women, and it is known to be the most prevalent endocrine malignancy worldwide, with its incidence continuing to increase in recent years (Pellegriti et al, 2013). Novel circulating protein biomarkers for thyroid cancer determined through data-independent acquisition mass spectrometry. Methods: Proteomic analysis of the human serum was performed through data-independent acquisition mass spectrometry for 29 patients with TC (stages I–IV): 13 cases of papillary TC (PTC), 10 cases of medullary TC (MTC), and six cases follicular TC (FTC). CFHR1 exhibited higher diagnostic performance in distinguishing patients with MTC from those with PTC (P < 0.001), with a sensitivity of 100.0%, specificity of 85.08%, area under the curve of 0.93, and detection cut-off of 0.92 ng/mL. Conclusion: CFHR1 may serve as a novel biomarker to distinguish PTC from MTC with high sensitivity and specificity
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
